Daiichi Sankyo Sold $1.55B Consumer Unit to Suntory

Daiichi Sankyo will sell its consumer health subsidiary to Suntory Holdings for 246.5 billion yen, about $1.55 billion, paid in tranches over three years.

This is pharma’s familiar OTC exit: carve out the consumer portfolio, pocket the cash, and tell investors the company is focused on innovation. Daiichi’s own words: it will concentrate on its “innovative medicines franchise, particularly the oncology business.” Suntory, the Japanese beverage giant, becomes the buyer.

What does Suntory actually get? Daiichi hasn’t itemized the consumer assets, but $1.55 billion for a Japanese pharma OTC unit is a real price. The tranche structure across three years means Suntory isn’t writing one check, and staggered payments like this often signal either regulatory sequencing or market-by-market handoffs.

Across the same news cycle, AbbVie paid $30 million upfront to Haisco Pharmaceutical for ex-China rights to two NaV1.8 inhibitors, with $715 million more riding on milestones. That’s 96 cents of every dollar in the $745 million deal sitting in contingent value.

The assets target acute pain and are positioned as rivals to Vertex’s Journavx. Both Haisco drugs share the mechanism: one is a phase 1 intravenous candidate, the other a preclinical oral. AbbVie’s $715 million in milestones sits in contingent value.

Daiichi’s deal completes across roughly three years from signing.

— Diana Kowalski